Protocol Ledger

NCT05227209 · Phase III · TERMINATED

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Interventional Phase III clinical trial protocol NCT05227209 sponsored by Sumitomo Pharma America in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-17 Enrollment: 64 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05227209
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)64 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05227209
Protocol FieldVerified Registry Value
NCT IdentifierNCT05227209
Consolidated Lead SponsorSumitomo Pharma America
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment64 participants (ACTUAL)
Registered Start Date2022-03-17
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05227209
Hospital Research SiteLocationSite Profile
Advanced Research Center, Inc.Anaheim, CAOpen Hospital Dossier ->
Clinical Neuroscience Solutions, Inc.Jacksonville, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI